Table 2 Prevalence of demographic and clinical characteristics in men with prostate cancer living in outer regional/remote areas of Tasmania relative to their counterparts living in inner regional areas.

Age at diagnosis

< 60

n.a

60–64

0.69 (0.55–0.86)

65–69

1.26 (1.07–1.50)

 ≥ 70

1.14 (1.02–1.28)

SEIFA quintile

1 (Most disadvantaged)

n.a

n.a

2

3.12 (2.63–3.70)

3.13 (2.63–3.72)

3

2.53 (2.03–3.14)

2.56 (2.04–3.20)

4

0.55 (0.45–0.68)

0.56 (0.45–0.69)

5 (Most advantaged)

0.11 (0.07–0.16)

0.10 (0.07–0.15)

Method of diagnosis

TRUS

n.a

n.a

TURP

1.13 (0.85–1.50)

0.94 (0.74–1.19)

TP Biopsy

1.05 (0.97–1.13)

1.07 (0.99–1.15)

Other

0.97 (0.47–1.98)

0.81 (0.40–1.64)

Diagnostic PSA (ng/mL)

 ≤ 4

n.a

n.a

n.a

4.01–10

0.92 (0.83–1.01)

0.99 (0.90–1.08)

1.00 (0.90–1.11)

10.01–20

1.35 (1.13–1.62)

1.24 (1.02–1.49)

1.11 (0.93–1.32)

 > 20.01

1.10 (0.84–1.45)

0.91 (0.73–1.14)

0.88 (0.75–1.02)

Gleason score

< 7

n.a

n.a

n.a

7 (3 + 4)

0.99 (0.84–1.17)

1.04 (0.87–1.23)

1.08 (0.90–1.3)

7 (4 + 3)

1.27 (1.01–1.59)

1.20 (0.94–1.53)

1.02 (0.78–1.3)

 ≥ 8

1.21 (1.02–1.43)

0.98 (0.82–1.16)

1.20 (0.99–1.46)

NCCN risk

Low

0.70 (0.58–0.84)

0.75 (0.62–0.89)

0.88 (0.73–1.08)

Intermediate

n.a

n.a

n.a

high

1.30 (1.11–1.52)

1.31 (1.13–1.52)

1.22 (1.01–1.47)

Very high/metastatic

0.99 (0.74–1.32)

0.99 (0.74–1.31)

0.87 (0.58–1.29)

Diagnostic facility

Public

n.a

n.a

Private

0.82 (0.76–0.88)

0.82 (0.76–0.87)

Treatment facility (active treatment)

Public

n.a

n.a

Private

0.83 (0.72–0.95)

0.84 (0.73–0.97)